LM

Lauren Martz

Person

Heard in 5 episodes across 1 show since Oct 2026

Lauren Martz is the Executive Director of Biopharma Intelligence at BioCentury Inc. She is known for her work in biopharmaceutical intelligence and analysis.

Email alerts

Episodes

5
across 1 show

First heard

Oct 2026

Guest appearances

4

Episodes per month

Public PodLume episodes featuring it, over the last year.

Show the data
MonthEpisodes
Dec 20250
Jan 20260
Feb 20260
Mar 20260
Apr 20260
May 20260
Jun 20260
Jul 20260
Aug 20260
Sep 20260
Oct 20263
Nov 20262

Email alert

Email me when Lauren Martz comes up on a podcast

One email a week at most, with the new episodes that mention Lauren Martz. Free, no account needed, unsubscribe in one click.

What Lauren Martz has said on podcasts

24 statements

  1. on PelacarsenNegativeNov 10, 2026· BioCentury This Week

    Pelacarsen showed no efficacy across tested trial subgroups.

    “Pella-Carson really didn't show any efficacy at all against any of the subgroups that were tested in this trial.”

    Listen at 18:02

    Open the episode · Ep. 397 - What the U.S. midterms mean for biopharma
  2. on PelacarsenNeutralNov 10, 2026· BioCentury This Week

    Pelacarsen reduced Lp(a) by approximately 80%.

    “this was about 80%.”

    Listen at 19:07

    Open the episode · Ep. 397 - What the U.S. midterms mean for biopharma
  3. on Lp(a)-lowering therapyPositiveNov 10, 2026· BioCentury This Week

    Lp(a)-lowering therapy may work when used earlier or for primary prevention.

    “this may work if you use it in a primary prevention setting or much earlier.”

    Listen at 19:21

    Open the episode · Ep. 397 - What the U.S. midterms mean for biopharma
See all 24 statements →

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

5 episodes featuring Lauren Martz, newest first